| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b …
Over the last 12 months, insiders at Mereo BioPharma Group plc have bought $0 and sold $0 worth of Mereo BioPharma Group plc stock.
On average, over the past 5 years, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2024-09-13 | Sale | Scots-Knight Denise | Chief Executive Officer | 60,046 0.0454% | $4.22 | $253,454 | -35.98% | |
| 2024-09-13 | Sale | Sermon Charles | General Counsel | 20,946 0.0158% | $4.22 | $88,413 | -35.98% | |
| 2024-09-13 | Sale | Fox Christine Ann | Chief Financial Officer | 19,158 0.0145% | $4.22 | $80,866 | -35.98% | |
| 2024-09-13 | Sale | Lewicki John A. | Chief Scientific Officer | 10,937 0.0083% | $4.22 | $46,165 | -35.98% | |
| 2024-09-13 | Sale | Hughes-Wilson Alexandra | See Remarks | 100,312 0.0759% | $4.22 | $423,417 | -35.98% | |
| 2024-09-12 | Sale | Scots-Knight Denise | Chief Executive Officer | 28,611 0.0229% | $4.47 | $127,968 | -37.59% | |
| 2024-09-12 | Sale | Sermon Charles | General Counsel | 9,980 0.008% | $4.47 | $44,638 | -37.59% | |
| 2024-09-12 | Sale | Hughes-Wilson Alexandra | See Remarks | 47,798 0.0383% | $4.47 | $213,786 | -37.59% | |
| 2024-09-12 | Sale | Fox Christine Ann | Chief Financial Officer | 9,128 0.0073% | $4.47 | $40,827 | -37.59% | |
| 2024-09-12 | Sale | Lewicki John A. | Chief Scientific Officer | 5,212 0.0042% | $4.47 | $23,312 | -37.59% | |
| 2024-08-22 | Sale | PAKIANATHAN DEEPIKA | director | 105,244 0.0836% | $4.43 | $466,210 | -36.36% | |
| 2024-06-26 | Sale | Scots-Knight Denise | Chief Executive Officer | 92,273 0.0561% | $3.39 | $313,101 | -0.86% | |
| 2024-06-26 | Sale | Sermon Charles | General Counsel | 32,187 0.0196% | $3.39 | $109,217 | -0.86% | |
| 2024-06-26 | Sale | Fox Christine Ann | Chief Financial Officer | 29,439 0.0179% | $3.39 | $99,892 | -0.86% | |
| 2024-06-26 | Sale | Lewicki John A. | Chief Scientific Officer | 16,808 0.0102% | $3.39 | $57,033 | -0.86% | |
| 2024-06-26 | Sale | Hughes-Wilson Alexandra | See Remarks | 22,968 0.014% | $3.39 | $77,935 | -0.86% | |
| 2024-06-25 | Sale | Scots-Knight Denise | Chief Executive Officer | 40,712 0.027% | $3.69 | $150,386 | -0.71% | |
| 2024-06-25 | Sale | Sermon Charles | General Counsel | 14,202 0.0094% | $3.69 | $52,461 | -0.71% | |
| 2024-06-25 | Sale | Fox Christine Ann | Chief Financial Officer | 12,990 0.0086% | $3.69 | $47,984 | -0.71% | |
| 2024-06-25 | Sale | Lewicki John A. | Chief Scientific Officer | 7,416 0.0049% | $3.69 | $27,394 | -0.71% |
| Increased Positions | 37 | +28.91% | 30M | +29.68% |
| Decreased Positions | 57 | -44.53% | 68M | -67.79% |
| New Positions | 22 | New | 12M | New |
| Sold Out Positions | 37 | Sold Out | 61M | Sold Out |
| Total Postitions | 108 | -15.63% | 62M | -38.11% |
| Janus Henderson Group Plc | $8,308.00 | 2.05% | 16.29M | -1M | -7.91% | 2025-09-30 |
| Rubric Capital Management Lp | $7,807.00 | 1.92% | 15.31M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $4,814.00 | 1.19% | 9.44M | 0 | 0% | 2025-09-30 |
| Mangrove Partners Im, Llc | $3,973.00 | 0.98% | 7.79M | -845,905 | -9.79% | 2025-09-30 |
| Aberdeen Group Plc | $2,825.00 | 0.7% | 5.54M | +3M | +82.86% | 2025-09-30 |
| 683 Capital Management, Llc | $2,486.00 | 0.61% | 4.88M | +525,000 | +12.07% | 2025-09-30 |
| Rock Springs Capital Management Lp | $2,331.00 | 0.57% | 4.57M | +105,357 | +2.36% | 2025-09-30 |
| Clearline Capital Lp | $1,955.00 | 0.48% | 3.83M | +216,000 | +5.97% | 2025-09-30 |
| Alkeon Capital Management Llc | $1,886.00 | 0.47% | 3.7M | -1M | -21.29% | 2025-09-30 |
| Morgan Stanley | $1,707.00 | 0.42% | 3.35M | +3M | +326.08% | 2025-09-30 |